• PHP20 SURVIVAL ANALYSIS IN SEDATED INTENSIVE CARE UNIT (ICU) PATIENTS

    May 1, 2002, 00:00

  • PMI22 ITEM REDUCTION OF A NEW PHARMACEUTICAL THERAPY RELATED QUALITY OF LIFE (PTRQOL) INSTRUMENT- FACTOR ANALYSIS METHOD OR CLINICAL IMPACT METHOD?

    May 1, 2002, 00:00

  • PMH11 A SWEDISH PHARMACOECONOMIC EVALUATION OF ESCITALOPRAM, A NEW SSRI- COMPARISON OF COST-EFFECTIVENESS BETWEEN ESCITALOPRAM, CITALOPRAM, FLUOXETINE AND VENLAFAXINE

    May 1, 2002, 00:00

  • PAO6 COST-EFFECTIVENESS OF BISPHOSPHONATE THERAPIES IN POST-MENOPAUSAL WOMEN- A THRESHOLD ANALYSIS

    May 1, 2002, 00:00

  • MI7 HOSPITAL-SPECIFIC RELATIVE INTENSITY SCORES FOR PHARMACEUTICAL SERVICES

    May 1, 2002, 00:00

  • PHP39 IMPACT OF AN INCREASE IN PRESCRIPTION CO-PAYMENT ON DRUG UTILIZATION

    May 1, 2002, 00:00

  • PAO1 CARDIORENAL EFFECTS AND COSTS OF COX-2 INHIBITORS IN A MANAGED CARE ORGANIZATION

    May 1, 2002, 00:00

  • PRA1 ANALYSIS OF NASAL STEROID DOSING PATTERNS IN A LARGE SAMPLE FROM A PRESCRIPTION DATABASE

    May 1, 2002, 00:00

  • PMI21 EVALUATING HEALTH PLAN MANAGEMENT OF EMPLOYER INDIRECT COSTS- METHODOLOGICAL ISSUES

    May 1, 2002, 00:00

  • PAO11 COST-EFFECTIVENESS OF VARIOUS TREATMENT STRATEGIES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN POLAND

    May 1, 2002, 00:00

  • PMW1 LIFE EXPECTANCY PREDICTION OF HRT FOR PRIMARY PREVENTION STRATEGIES IN POST-MENOPAUSAL WOMEN

    May 1, 2002, 00:00

  • PMW3 COVERAGE OF SILDENAFIL CITRATE BY EMPLOYERS AND HEALTH PLANS- LOWER THAN EXPECTED PHARMACY BENEFIT COSTS AND ADDITIONAL HEALTH BENEFITS

    May 1, 2002, 00:00

  • IN1 META-ANALYSIS OF UTILITY ESTIMATES- HIV/AIDS AND STROKE

    May 1, 2002, 00:00

  • PGI9 THE COST-EFFECTIVENESS OF INTRAVENOUS PROTON PUMP INHIBITOR CONTINUOUS INFUSION (IV PPI) ADMINISTERED PRIOR TO ENDOSCOPY IN THE TREATMENT OF PATIENTS WITH NON-VARICEAL UPPER GI BLEEDING

    May 1, 2002, 00:00

  • PMH25 COST IMPACT OF DEPOT DOSAGE FORMS OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS

    May 1, 2002, 00:00

  • PMI37 INTEGRATION OF INTERNATIONAL INPUT INTO INSTRUMENT DESIGN- TRANSLATABILITY ASSESSMENT

    May 1, 2002, 00:00

  • PHP55 CONTENT ANALYSIS OF QUALITY OF LIFE AND PHARMACOECONOMIC MESSAGES IN PHARMACEUTICAL PRODUCT ADVERTISEMENTS

    May 1, 2002, 00:00

  • IN4 THE COST OF ANTIRETROVIRAL THERAPY IN THREE CENTRAL AMERICAN COUNTRIES

    May 1, 2002, 00:00

  • PMI17 METHODS FOR ASSESSING THE VALUE OF ANTIPSYCHOTIC TREATMENT- A NEW PERSPECTIVE FOR INTERPRETING SERVICE UTILIZATION

    May 1, 2002, 00:00

  • PUK5 INCIDENCE AND COST ASSOCIATED WITH PHARMACOLOGICAL TREATMENT FOR EMPLOYEES DIAGNOSED WITH URINARY AND OVERACTIVE BLADDER DISORDERS

    May 1, 2002, 00:00

  • PCV16 DIFFERENCES IN HOSPITAL LENGTH-OF-STAY, CHARGES AND MORTALITY IN CONGESTIVE HEART FAILURE PATIENTS

    May 1, 2002, 00:00

  • PGI12 FACTOR STRUCTURE AND FURTHER VALIDATION OF THE GASTROESOPHAGEAL REFLUX DISEASE (GERD) SYMPTOM ASSESSMENT SCALE

    May 1, 2002, 00:00

  • PES6 COST EFFECTIVENESS OF PHOTODYNAMIC THERAPY (PDT) WITH VERTEPORFIN IN THE UK

    May 1, 2002, 00:00

  • PCV31 COST-EFFECTIVENESS ANALYSIS OF THE ARCTIC SUNTM MODEL 100 FOR TEMPERATURE MANAGEMENT IN OFF-PUMP CORONARY ARTERY BYPASS SURGERY

    May 1, 2002, 00:00

  • PHP5 IMPACT OF MULTI-TIERED PHARMACY BENEFITS ON MEDICATION ADHERENCE

    May 1, 2002, 00:00

  • PAO19 UTILIZATION CHARACTERISTICS OF COX-2 INHIBITORS IN A LARGE MANAGED CARE HEALTH PLAN

    May 1, 2002, 00:00

  • PIN12 COSTS OF TREATMENT FOR AMBULATORY LOWER RESPIRATORY TRACT INFECTION IN QUEBEC SENIORS

    May 1, 2002, 00:00

  • PES9 PSORIASIS AND EVERYDAY LIFE- FIRST RESULTS

    May 1, 2002, 00:00

  • PCV19 THE COST-EFFECTIVENESS ANALYSIS OF ASPIRIN FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE

    May 1, 2002, 00:00

  • PMH4 SUPPLEMENTAL ANALYSIS OF THE QUETIAPINE EXPERIENCE WITH SAFETY AND TOLERABILITY (QUEST) STUDY

    May 1, 2002, 00:00

  • PMI34 A LOGICAL PROBLEM IN VIEWING UTILITY THEORY AS NORMATIVE

    May 1, 2002, 00:00

  • PMI33 LITERATURE REVIEW OF GUIDELINES FOR CROSS-CULTURAL ADAPTATION OF HRQL MEASURES- UPDATED RESULTS

    May 1, 2002, 00:00

  • PHP41 VALUE OF VACCINATION

    May 1, 2002, 00:00

  • PCN9 PHARMACOECONOMIC ANALYSES OF AVAILABLE CHEMOTHERAPEUTIC AGENTS FOR THE MANAGEMENT OF ADVANCED COLORECTAL CANCER

    May 1, 2002, 00:00

  • HP3 IMPROVING THE SAFETY OF AMIODARONE IN THE CONGESTIVE HEART FAILURE POPULATION- BASELINE ASSESSMENT OF COMPLIANCE WITH NATIONAL GUIDELINES IN A LARGE CHF CLINIC

    May 1, 2002, 00:00

  • PAO4 COST ANALYSIS OF A 12-WEEK CYCLE OF THERAPY WITH CELECOXIB VS. CONVENTIONAL NSAIDS IN PATIENTS WITH OSTEOARTHRITIS

    May 1, 2002, 00:00

  • PCV26 FIRST RUSSIAN EXPERIENCE OF ASSESSING WILLINGNESS TO PAY- AVOIDING AMPUTATION IN CASE OF CRITICAL LIMB ISCHEMIA

    May 1, 2002, 00:00

  • PAO15 IMPACT OF ETANERCEPT FOR RHEUMATOID ARTHRITIS (RA) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND FUNCTIONAL STATUS IN A NATURALISTIC SETTING

    May 1, 2002, 00:00

  • PMH39 BASELINE COMPARISON OF PATIENTS WITH SCHIZOPHRENIA USING OLANZAPINE, RISPERIDONE AND TYPICAL ANTIPSYCHOTICS IN CALIFORNIA MEDICAID PROGRAM

    May 1, 2002, 00:00

  • PMH23 THE COST CONSEQUENCES OF CONTINUED TREATMENT-RESISTANCE IN DEPRESSION

    May 1, 2002, 00:00

  • PMH16 PREVALENCE AND COSTS OF ACCIDENTS AMONG ATTENTION-DEFICIT/HYPERACTIVITY DISORDER PATIENTS

    May 1, 2002, 00:00

  • PCV17 COST-EFFECTIVENESS OF RAMIPRIL (ALTACE) IN PATIENTS POST-REVASCULARIZATION

    May 1, 2002, 00:00

  • PCN14 GENDER, FAMILY HISTORY AND OPTIMAL LIFETIME SCREENING PROGRAMS FOR COLORECTAL CANCER- A MODEL BASED ECONOMIC EVALUATION

    May 1, 2002, 00:00

  • AR4 PSYCHOMETRIC PROPERTIES OF THE ACUTE BRONCHITIS SYMPTOM SEVERITY SCALE IN AN INTERNATIONAL SAMPLE

    May 1, 2002, 00:00

  • CV3 LONG-TERM COSTS AND CLINICAL CONSEQUENCES OF DIFFERENT LEVELS OF 2-HOUR POST PRANDIAL BLOOD GLUCOSE IN NON-DIABETES PATIENTS

    May 1, 2002, 00:00

  • PRA16 CULTURAL ADAPTATION AND VALIDATION OF CHILDHOOD ASTHMA QUESTIONNAIRE VERSION B (CAQ-B) FOR SINGAPORE CHILDREN

    May 1, 2002, 00:00

  • PMW2 ECONOMIC ANALYSIS OF SILDENAFIL CITRATE ADD-ON TO TREAT SSRI-INDUCED ERECTILE DYSFUNCTION

    May 1, 2002, 00:00

  • PMH2 ESTABLISHING THE EXPECTED RATE OF COGNITIVE DECLINE IN ALZHEIMER'S DISEASE

    May 1, 2002, 00:00

  • PDB13 TRENDS IN INSULIN THERAPY FOR TREATMENT OF TYPE-2 DIABETES MELLITUS

    May 1, 2002, 00:00

  • PCV15 TOTAL DIRECT MEDICAL AND DRUG COSTS OF NON-ADHERENCE TO STATIN THERAPY WITHIN THE FIRST YEAR OF TREATMENT

    May 1, 2002, 00:00

  • PCV29 INFLUENCE OF COMORBID CONDITIONS IN THE HOSPITALIZATION OF ANGINA PATIENTS

    May 1, 2002, 00:00

  • PIN11 INITIAL ANTIMICROBIAL THERAPY AND OUTCOMES IN PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP)

    May 1, 2002, 00:00

  • PHP31 OUTCOMES AND COSTS OF ACUTE TREATMENT OF TRAUMATIC BRAIN INJURY

    May 1, 2002, 00:00

  • PGI8 A COST ANALYSIS OF DIAGNOSTIC AND TREATMENT STRATEGIES IN PATIENTS WITH SYMPTOMS OF POUCHITIS

    May 1, 2002, 00:00

  • PMH30 INFLUENCE OF CAREGIVING ON HEALTH STATUS OF DEMENTIA CAREGIVERS

    May 1, 2002, 00:00

  • Automated Current Health Time-Trade-Off Assessments in Women's Health

    Mar 1, 2002, 00:00

  • The Bias Against New Innovations in Health Care- Value Uncertainty and Willingness to Pay

    Mar 1, 2002, 00:00

  • Do Health-Care Decision Makers Find Economic Evaluations Useful? The Findings of Focus Group Research in UK Health Authorities

    Mar 1, 2002, 00:00

  • Letters to The Editor

    Mar 1, 2002, 00:00

  • Development of a Decision-Analytic Model of Stroke Care in the United States and Europe

    Mar 1, 2002, 00:00

  • Use of Economic Evaluation in Decision Making- What Needs to Change?

    Mar 1, 2002, 00:00

  • Is Sepsis Accurately Coded on Hospital Bills?

    Mar 1, 2002, 00:00

  • Validity of a Work Productivity and Activity Impairment Questionnaire for Patients with Symptoms of Gastro-Esophageal Reflux Disease (WPAI-GERD)—Results from a Cross-Sectional Study

    Mar 1, 2002, 00:00

  • Letter to the Editor

    Jan 1, 2002, 00:00

  • The Incidence and Cost of Hospitalization for 5-FU Toxicity among Medicare Beneficiaries with Metastatic Colorectal Cancer

    Jan 1, 2002, 00:00

  • The Economics of Gene Therapy and of Pharmacogenetics

    Jan 1, 2002, 00:00

  • The Direct Cost and Incidence of Systemic Fungal Infections

    Jan 1, 2002, 00:00

  • A Method for Identifying the Financial Burden of Hospitalized Infants on Families

    Jan 1, 2002, 00:00

  • The Value of Economic Modeling Studies in the Evaluation of Treatment Strategies for Multiple Sclerosis

    Jan 1, 2002, 00:00

  • Outcomes Research in the Health-Care System- Driven by Results

    Jan 1, 2002, 00:00

  • Cost-Effectiveness Analysis of Interferon Beta in Multiple Sclerosis- A Markov Process Analysis

    Jan 1, 2002, 00:00

  • Regulatory Issues for Health-Related Quality of Life— PhRMA Health Outcomes Committee Workshop, 1999

    Jan 1, 2002, 00:00

  • PAM14- TREATMENT WITH LEFLUNOMIDE IMPROVES THE UTILITY OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS- AN APPLICATION OF THE SF-6D

    Sep 1, 2001, 00:00

  • PRP7- COST-EFFECTIVENESS ANALYSIS OF SEQUENTIAL TREATMENT WITH ALMITRINE BISMESYLATE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Sep 1, 2001, 00:00

  • PHP25- THE USE OF ATC/DDD METHODOLOGY FOR REVIEWING COST OF DRUG EXPOSURE AT THE NATIONAL LEVEL

    Sep 1, 2001, 00:00

  • PAM18- PERFORMANCE ASSESSMENT OF TWO FATIGUE INSTRUMENTS IN AN EARLY RHEUMATOID ARTHRITIS COHORT

    Sep 1, 2001, 00:00

  • WW8- CONSTRUCTING EPISODES OF CARE FROM CLAIMS DATA- APPLICATIONS TO PHARMACOECONOMIC AND OUTCOMES RESEARCH

    Sep 1, 2001, 00:00

  • PGI8- RAPID IMPACT OF RABEPRAZOLE ON SYMPTOM DISTRESS AMONG PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE

    Sep 1, 2001, 00:00

  • DB3- A DYNAMIC, THREE-PART MODEL FOR PREDICTING HOSPITAL COSTS IN TYPE 2 DIABETIC PATIENTS

    Sep 1, 2001, 00:00

  • CV5- ORLISTAT IN OBESE TYPE 2 DIABETIC PATIENTS- ASSESSMENT OF LONG TERM OUTCOMES AND COST-EFFECTIVENESS

    Sep 1, 2001, 00:00

  • PWM3- ERECTILE DYSFUNCTION- A PROSPECTIVE STUDY OF PATIENTS SEEKING THERAPY

    Sep 1, 2001, 00:00

  • PCV4- ASSESSING QUALITY OF LIFE IN PATIENTS SIX MONTHS AFTER A MYOCARDIAL INFARCTION USING THE SF-12

    Sep 1, 2001, 00:00

  • PMI5- A PROBLEM WITH STOCHASTIC ECONOMIC EVALUATION WHEN THE TIME HORIZONS FOR THE COST AND EFFECTIVENESS MEASUREMENTS ARE ASYMMETRICAL

    Sep 1, 2001, 00:00

  • PKU3- CUMULATIVE INCIDENCE AND TOTAL COSTS ASSOCIATED WITH URINARY AND OVERACTIVE BLADDER DISORDERS IN EMPLOYED POPULATIONS

    Sep 1, 2001, 00:00

  • PMH19- RISK OF HOSPITALIZATION FOR PATIENTS WITH BIPOLAR DISORDER

    Sep 1, 2001, 00:00

  • PEE4- THE FRENCH VERSION OF THE PSORIASIS DISABILITY INDEX

    Sep 1, 2001, 00:00

  • PMH3- IS DEPRESSION THE MAJOR CAUSE OF IMPAIRED QUALITY OF LIFE IN SCHIZOPHRENIC PATIENTS?

    Sep 1, 2001, 00:00

  • PMH34- SWITCHING AND AUGMENTATION OF ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS

    Sep 1, 2001, 00:00

  • PPN6- VALIDATION OF THE 24 HOUR HEADACHE DISABILITY QUESTIONNAIRE (DISQ-24) IN A SAMPLE OF HEADACHE SUFFERERS

    Sep 1, 2001, 00:00

  • PIN8- A COST-BENEFIT ANALYSIS OF INFLUENZA VACCINATION IN A COMPANY IN ITALY (ENI SPA)

    Sep 1, 2001, 00:00

  • PEE3- DRY-EYE RELATED INCREASES IN HEALTH CARE UTILIZATION AND EXPENDITURES

    Sep 1, 2001, 00:00

  • HP1- VALIDITY OF THE MINIMUM-DATA-SET-BASED QUALITY INDICATOR FOR DETERMINING THE PREVALENCE OF ANTIPSYCHOTIC MEDICATION USAGE AMONG LOW RISK NURSING HOME RESIDENTS- A STATEWIDE ASSESSMENT

    Sep 1, 2001, 00:00

  • MS1- COST-EFFECTIVENESS OF INTERVENTIONS FOR LATERAL EPICONDYLITIS- RESULTS FROM A RANDOMIZED CONTROLLED TRIAL IN PRIMARY CARE

    Sep 1, 2001, 00:00

  • EM3- RESPONSE BIAS AMONG LIKELY CLINICAL TRIAL PARTICIPANTS

    Sep 1, 2001, 00:00

  • WW16- PATIENT REGISTRIES- THEIR VALUE IN OUTCOMES RESEARCH

    Sep 1, 2001, 00:00

  • PMH20- COMPARISON OF ADVERSE DRUG EVENTS (ADE) ASSOCIATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) IN TWO MANAGED CARE ORGANIZATIONS (MCO)

    Sep 1, 2001, 00:00

  • PCV26- CARING FOR HYPERTENSION ON INITIATION- COSTS AND EFFECTIVENESS (CHOICE). DESIGN AND RATIONALE OF A NATURALISTIC STUDY

    Sep 1, 2001, 00:00

  • PCV1- LONG-TERM COST-BENEFIT SIMULATION OF SIBUTRAMINE USING A MARKOV MODEL

    Sep 1, 2001, 00:00

  • PMH13- PRE-TREATMENT PATIENT DIFFERENCES- CHOICE OF DRUG THERAPY WITHIN SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PDB1- DIABETIC MANAGEMENT THROUGH ORAL GLUCOSE LOWERING AGENTS- TREATMENT PATTERN, COST AND UTILIZATION ANALYSIS

    Sep 1, 2001, 00:00

  • PID6- HIV/AIDS HEALTH STATE UTILITIES USING COMMUNITY AND PATIENT PREFERENCE WEIGHTS- WHEN DOES IT MATTER?

    Sep 1, 2001, 00:00

  • PMI12- CAREGIVER-BURDEN MEASURES IN ALZHEIMERS DISEASE- A COMPREHENSIVE REVIEW

    Sep 1, 2001, 00:00

  • PDG4- THE DIFFERENTIAL EFFECT OF SULPHONYLUREA OR BIGUANIDE DRUGS ON CARDIAC REVASCULARIZATION PROCEDURES IN DIABETICS

    Sep 1, 2001, 00:00

  • DB2- BOTTOM UP VERSUS TOP DOWN COST ESTIMATES FOR TYPE 2 DIABETES

    Sep 1, 2001, 00:00

  • PDG10- A PHARMACOECONOMIC MODEL OF HbA1c CONTROL IN THE TREATMENT OF TYPE 2 DIABETES

    Sep 1, 2001, 00:00

  • PCV13- EFFECT OF AMLODIPINE TREATMENT ON CARDIOVASCULAR DISEASE-RELATED HOSPITALIZATIONS AND COSTS IN PATIENTS WITH CORONARY ARTERY DISEASE IN SPAIN

    Sep 1, 2001, 00:00

  • PIN24- THE DEVELOPMENT AND VALIDATION OF THE INFLUENZA DAILY DISRUPTION QUESTIONNAIRE (IDDQ)

    Sep 1, 2001, 00:00

  • PMH20- DOSING OF BENZODIAZEPINE HYPNOTICS IN ELDERLY PATIENTS

    Sep 1, 2001, 00:00

  • PCV26- HOW MUCH DOES ONE GRAM OF HUMAN HEART MUSCLE COST?

    Sep 1, 2001, 00:00

  • PAM11- APPLYING BACKGROUND RISK DISTRIBUTION TO EVALUATE THE COST-EFFECTIVENESS OF THREE PREVENTIVE DRUG THERAPIES FOR OSTEOPOROTIC FRACTURES

    Sep 1, 2001, 00:00

  • MS4- A SYSTEMATIC REVIEW OF HEALTH STATE VALUES FOR OSTEOPOROSIS RELATED CONDITIONS

    Sep 1, 2001, 00:00

  • PWM2- A COST-MINIMIZATION ANALYSIS COMPARING MIRENA WITH ORAL CONTRACEPTIVES

    Sep 1, 2001, 00:00

  • PCN7- ECONOMIC EVALUATION OF GEMZAR AND BEST SUPPORTIVE CARE (BSC) RELATIVE TO BEST SUPPORTIVE CARE ALONE IN THE TREATMENT OF NON SMALL CELL LUNG (NSCLC) CANCER IN THE UK

    Sep 1, 2001, 00:00

  • PCN2- WHICH VARIABLES DO METASTATIC BREAST CANCER PATIENTS AND ONCOLOGY NURSES ANCHOR ON WHEN USING THE EUROQOL DESCRIPTIVE SYSTEM IN MEASURING UTILITIES WITH THE STANDARD GAMBLE TECHNIQUE?

    Sep 1, 2001, 00:00

  • PCV27- A PHARMACOECONOMIC MODEL TO EVALUATE TREATMENT OPTIONS FOR DVT PHARMACOPROPHYLAXIS

    Sep 1, 2001, 00:00

  • PCV15- CHRONIC VENOUS INSUFFICENCY (CVI) IN POLAND-A COST OF ILLNESS STUDY

    Sep 1, 2001, 00:00

  • PMI9- USE OF AN AUTOMATED PROCESS TO SCAN AND INTERPRET MANUALLY-CODED DATA FORMS IN PHARMACOECONOMICS RESEARCH

    Sep 1, 2001, 00:00

  • PMH8- IMPACT OF CURRENT ANTIDEPRESSANTS ON COGNITION IN OLDER PATIENTS WITH DEPRESSION

    Sep 1, 2001, 00:00

  • PEE1- LONG TERM CLINICAL CONSEQUENCES OF ND-YAG LASER CAPSULOTOMY FOLLOWING POSTERIOR CAPSULAR OPACIFICATION AFTER CATARACT SURGERY - A MARKOV MODEL APPROACH

    Sep 1, 2001, 00:00

  • PMH4- ASSESSMENT OF PATIENTS ATTITUDES TOWARD ANTIPSYCHOTIC TREATMENT IN A 40-WEEK RANDOMIZED, CONTROLLED TRIAL

    Sep 1, 2001, 00:00

  • PAM19- A REVIEW OF FUNCTIONAL STATUS MEASURES FOR WORKERS WITH UPPER EXTREMITY DISORDERS

    Sep 1, 2001, 00:00

  • PCV25- CHD RISK FACTORS AND THERAPY DURATION OF HMG-COA REDUCTASE INHIBITORS (STATINS) IN A MEDICAID POPULATION

    Sep 1, 2001, 00:00

  • PDG19- TRENDS IN USE OF ANTIDIABETICS IN THE CZECH REPUBLIC

    Sep 1, 2001, 00:00

  • PMH30- DIFFERENCES IN HEALTH CARE EXPENDITURES AMONG PATIENTS TREATED FOR DEPRESSION WITH OR WITHOUT ANXIETY

    Sep 1, 2001, 00:00

  • ND2- ASSESSING THE QUALITY OF LIFE IN PARKINSONS DISEASE

    Sep 1, 2001, 00:00

  • PQP10- NEGATIVE AFFECTIVITY- A SIGNIFICANT CONTAMINANT OF PATIENT REPORTED HEALTH RELATED QUALITY OF LIFE INSTRUMENTS (SF-36)

    Sep 1, 2001, 00:00

  • PEE1- ANTIBIOTIC PRESCRIBING PATTERNS FOR THE TREATMENT OF INITIAL ACUTE OTITIS MEDIA IN CHILDREN ENROLLED IN IOWA MEDICAID FROM 1990 THROUGH 1997

    Sep 1, 2001, 00:00

  • PRP8- LIFETIME COSTS OF COPD IN THE NETHERLANDS

    Sep 1, 2001, 00:00

  • PCN1- BASELINE ANEMIA AND RISK OF POOR RESPONSE TO CHEMOTHERAPY IN INTERMEDIATE GRADE NON-HODGKINS LYMPHOMA(IGNHL) PATIENTS

    Sep 1, 2001, 00:00

  • PMI7- PROBABILISTIC SENSITIVITY ANALYSIS FOR EVALUATING COST-UTILITY OF ENTACAPONE TREATMENT FOR PARKINSONS DISEASE

    Sep 1, 2001, 00:00

  • MH5- COST OF THE FIRST, SECOND AND SUBSEQUENT EPISODE OF DEPRESSION IN POLAND

    Sep 1, 2001, 00:00

  • PMH7- CHANGES IN SCHIZOPHRENIA-RELATED TOTAL DIRECT MEDICAL COSTS FOLLOWING INITIATION OF OLANZAPINE OR RISPERIDONE IN A PRIVATELY INSURED POPULATION IN THE UNITED STATES

    Sep 1, 2001, 00:00

  • PMH24- HEALTH-CARE RESOURCE USE AMONG CAREGIVERS OF PEOPLE WITH SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PGI7- BUDESONIDE CIR IS COST-EFFECTIVE IN MAINTENANCE THERAPY OF CROHNS DISEASE IN FINLAND

    Sep 1, 2001, 00:00

  • PMH35- PATTERNS OF ANTIDEPRESSANT AND ANTIPSYCHOTIC MEDICATION USE IN MEDICAID, 1995-1999

    Sep 1, 2001, 00:00

  • CH1- DEVELOPMENT OF A MINIMUM DATASET (MDS)-BASED COMORBIDITY INDEX FORA NURSING HOME POPULATION

    Sep 1, 2001, 00:00

  • PCN6- CAN ICD-9 CODES BE USED AS A PROXY FOR DISEASE STAGING IN ECONOMIC EVALUATIONS?

    Sep 1, 2001, 00:00

  • PHP21- SINGLE EUROPEAN-LEVEL COST-EFFECTIVENESS ANALYSIS- OVER THE FOURTH HURDLE AND INTO THE DITCH?

    Sep 1, 2001, 00:00

  • MH1- SOAP-51- A QUALITY OF LIFE SURVEY FOR COMMUNITY-RESIDING INDIVIDUALS WITH SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PCN18- QUALITY OF LIFE IN CANCER CLINICAL TRIALS - AN OVERVIEW OF APPROACHES WITHIN THE EORTC

    Sep 1, 2001, 00:00

  • PMA11- COMPARISON OF STATISTICAL TESTS FOR THE COST/EFFECTIVENESS RATIOS

    Sep 1, 2001, 00:00

  • PHP13- PHARMACOECONOMICS OF BLOOD TRANSFUSION SAFETY MEASURES- A REVIEW OF THE LITERATURE

    Sep 1, 2001, 00:00

  • PCN14- CHEMOTHERAPY-INDUCED NEUROPATHY IN OVARIAN CANCER COST EFFECTIVENESS ANALYSIS

    Sep 1, 2001, 00:00

  • PMI24- QUALITY OF LIFE- FUNCTIONING OR NEED FULFILMENT?

    Sep 1, 2001, 00:00

  • PHP1- INTEGRATING HEALTH ECONOMICS INTO THE PRODUCT DECISION- MAKING PROCESS- LESSONS LEARNED FROM DECISION-MAKERS

    Sep 1, 2001, 00:00

  • PCV11- THE COST-EFFECTIVENESS OF LEVOSIMENDAN IN SEVERE LOW-OUTPUT HEART FAILURE COMPARED TO DOBUTAMINE BASED ON AN INTERNATIONAL CLINICAL TRIAL (LIDO)

    Sep 1, 2001, 00:00

  • PMH23- DEINSTITUTIONALIZATION OF SCHIZOPHRENIC PATIENTS- COST-CONSEQUENCES AND POLICY IMPLICATION OF INTENSIVE CASE MANAGEMENT VERSUS STANDARD CASE MANAGEMENT

    Sep 1, 2001, 00:00

  • PIN10- DEVELOPMENT AND VALIDATION OF A 17-COUNTRY EUROPEAN PHARMACOECONOMIC MODEL- THE ONYCHOTREE STUDY

    Sep 1, 2001, 00:00

  • POD11- BENIGN PROSTATIC HYPERPLASIA-CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE- RISK OF SOMNOLENCE

    Sep 1, 2001, 00:00

  • PAM8- COST COMPARISON OF TREATING OSTEOPOROSIS PATIENTS WITH ESTROGENS OR SELECTIVE ESTROGEN RECEPTOR MODULATOR IN A MANAGED CARE POPULATION

    Sep 1, 2001, 00:00

  • PCV21- A HEALTH-ECONOMIC ANALYSIS OF THE USE OF AMLODIPINE IN PATIENTS UNDERGOING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY IN THE U.K

    Sep 1, 2001, 00:00

  • MH6- MODELLING THE COSTS OF ILLNESS AND THE COSTS OF RELAPSE IN THE MANAGEMENT OF SCHIZOPHRENIA IN THE UK

    Sep 1, 2001, 00:00

  • PMA18- THE AVANDIA WORLDWIDE AWARENESS REGISTRY (AWARE)- AN INTERNET-BASED PROGRAM FOR EVALUATION OF CLINICAL, HUMANISTIC AND ECONOMIC OUTCOMES OF PATIENTS WITH TYPE 2 DIABETES

    Sep 1, 2001, 00:00

  • PAR14- ASSESSMENT OF THE RELATIONSHIP BETWEEN DISEASE SEVERITY, QUALITY OF LIFE AND WILLINGNESS TO PAY IN ASTHMA

    Sep 1, 2001, 00:00

  • PCV17- ECONOMIC EVALUATION OF ENOXAPARIN IN PATIENTS WITH ACUTE MEDICAL ILLNESS- AN ITALIAN ECONOMIC STUDY FROM THE MEDENOX TRIAL

    Sep 1, 2001, 00:00

  • PMI1- SELF-REPORT OF HEALTH-RELATED LOST PRODUCTIVE TIME AT WORK- BIAS AND THE OPTIMAL RECALL PERIOD

    Sep 1, 2001, 00:00

  • PIN23- THE FIRST STEP TO GENERATING UTILITY FROM QUALITY OF LIFE- A COMPARISON OF ITEM PREFERENCES AND ITEM SEVERITY

    Sep 1, 2001, 00:00

  • PMH9- HEALTH CARE UTILIZATION AND COSTS IN SCHIZOPHRENIC PATIENTS TAKING RISPERIDONE VERSUS OLANZAPINE IN A VETERANS ADMINISTRATION POPULATION

    Sep 1, 2001, 00:00

  • PID7- OBSERVATIONAL EVALUATION OF HEALTH STATE UTILITIES AMONG A COHORT OF SEPSIS PATIENTS

    Sep 1, 2001, 00:00

  • PAO3- COST OF CARE FOR MEMBERS WITH ARTHRITIS-A MANAGED CARE PERSPECTIVE

    Sep 1, 2001, 00:00

  • CV2- INDIRECT COMPARISONS OF DRUGS USING META-ANALYSIS- VALIDATION OF RESULTS

    Sep 1, 2001, 00:00

  • PMH13- THE DIRECT COST OF RISPERIDONE VERSUS HALOPERIDOL THERAPY FOR CHRONIC SCHIZOPHRENIA IN POLAND

    Sep 1, 2001, 00:00

  • PMA4- AN ECONOMIC PROOF AND APPLICATION THAT FORMULARY RESTRICTIONS WITHIN DRUG CLASSES ALWAYS RESULT IN HIGHER COSTS

    Sep 1, 2001, 00:00

  • PWM1- PREMATURE BIRTH AND RESOURCE UTILIZATION IN A LARGE EMPLOYMENT BASED INDEPENDENT PRACTICE ASSOCIATION (IPA)

    Sep 1, 2001, 00:00

  • PID25- ECONOMIC EVALUATION OF MACROLIDES AND FLUOROQUINOLONES FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS

    Sep 1, 2001, 00:00

  • WW6- CONDUCTING COST-BENEFIT AND COST-UTILITY ANALYSES- A CONJOINT ANALYSIS APPROACH

    Sep 1, 2001, 00:00

  • PCV41- SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS 1442-ONE-YEAR-RESULTS OF A PROSPECTIVE PHARMACOECONOMIC STUDY

    Sep 1, 2001, 00:00

  • PEE4- WELFARE COSTS OF VISUAL IMPAIRMENT

    Sep 1, 2001, 00:00

  • PDB16- AN OVERVIEW OF PHARMACOECONOMICS IN TURKEY- COST ANALYSIS AND REIMBURSEMENT OF ANTIDIABETIC DRUGS

    Sep 1, 2001, 00:00

  • CN3- COST-EFFECTIVENESS ANALYSIS OF IRINOTECAN5FU/FA ALONE AS FIRST-LINE THERAPY IN ADVANCED COLORECTAL CANCER IN THE UK

    Sep 1, 2001, 00:00

  • PEE7- A COST COMPARISON STUDY OF COMMON PRACTICE AND BEST PRACTICE TREATMENT FOR PRIMARY OPEN-ANGLE GLAUCOMA IN THE UNITED STATES

    Sep 1, 2001, 00:00

  • PCV19- A COST-EFFECTIVENESS ANALYSIS OF THE USE OF CARVEDILOL COMPARED TO BISOPROLOL IN CHRONIC HEART FAILURE

    Sep 1, 2001, 00:00

  • CV6- ECONOMIC EVALUATION OF DALTEPARIN, ENOXAPARIN AND UNFRACTIONATED HEPARIN IN THE TREATMENT OF DEEP VEIN THROMBOSIS

    Sep 1, 2001, 00:00

  • PPN11- THE MIGRAINE IN FRANCE IN 2000- EPIDEMIOLOGICAL DATA

    Sep 1, 2001, 00:00

  • PAO11- ECONOMIC ANALYSIS OF THE GUIDELINES FOR THE MANAGEMENT OF CORTICOSTEROIDINDUCED OSTEOPOROSIS IN RESPIRATORY PATIENTS

    Sep 1, 2001, 00:00

  • PMH14- ANTIPSYCHOTIC COMPLIANCE EVALUATION - A POPULATION-BASED, MANAGED-CARE STUDY OF PERSISTENCE WITH INITIALLY PRESCRIBED ANTIPSYCHOTIC MEDICATION

    Sep 1, 2001, 00:00

  • WW1- METHODOLOGICAL COMPLEXITIES IN USING ADMINISTRATIVE CLAIMS DATABASES TO EVALUATE QUALITY OF CARE FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

    Sep 1, 2001, 00:00

  • PND12- TREATMENT AND HEALTH-CARE SATISFACTION AMONG PEOPLE WITH MIGRAINE HEADACHES

    Sep 1, 2001, 00:00

  • PPN17- ADDRESSING PARADOXES IN ECONOMIC EVALUATIONS (EES). AN EXAMPLE USING MOTOR NEURON DISEASE (MND)

    Sep 1, 2001, 00:00

  • PND4- THE IMPACT OF DRUG INTERACTIONS ON HOSPITALIZATION RATES FOR ALZHEIMERS PATIENTS TREATED WITH DONEPEZIL

    Sep 1, 2001, 00:00

  • POD10- THE BPE-PIT-AN ADAPTATION OF THE BPE-P FOR USE IN A MULTINATIONAL CLINICAL TRIAL

    Sep 1, 2001, 00:00

  • PRP1- A COMPARISON OF SIX PHONE INTERVIEWS DESIGNED TO MEASURE HEALTH-RELATED LOST PRODUCTIVE TIME AT WORK

    Sep 1, 2001, 00:00

  • PCN27- COST OF TREATMENT FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN THE UNITED STATES

    Sep 1, 2001, 00:00

  • PID10- EFFECTS OF LINEZOLID ON HOSPITAL LENGTH OF STAY IN METHICILLIN-RESISTANT STAPHYLOCOCCUS INFECTIONS ESTIMATED FROM MULTIVARIATE SURVIVAL ANALYSIS

    Sep 1, 2001, 00:00

  • HP4- PRICING OF PHARMACEUTICALS IN CANADA AND EUROPE- A COMPARATIVE ANALYSIS

    Sep 1, 2001, 00:00

  • PPN2- USE OF GALANTAMINE IN THE NETHERLANDS FOR THE TREATMENT OF MILD TO MODERATE ALZHEIMERS DISEASE

    Sep 1, 2001, 00:00

  • PMA15- CONDUCTING PHARMACOECONOMIC RESEARCH IN THE ABSENCE OF COUNTRY-SPECIFIC DATA

    Sep 1, 2001, 00:00

  • PCV22- COST-EFFECTIVENESS OF ENOXAPARIN AS VENOUS THROMBOEMBOLISM PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS

    Sep 1, 2001, 00:00

  • PHP26- THE POTENTIAL BENEFITS AND DRAWBACKS OF ALLOWING DIRECT-TO-CONSUMER ADVERTISING OF PHARMACEUTICALS IN EUROPE

    Sep 1, 2001, 00:00

  • PCV30- COST-EFFECTIVENESS MODEL OF THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION

    Sep 1, 2001, 00:00

  • PIN6- ESTIMATED COSTS TO CONDUCT A PHASE III CLINICAL TRIAL OF A NEW PULMONARY TUBERCULOSIS DRUG

    Sep 1, 2001, 00:00

  • WW7- BEYOND COST-EFFECTIVENESS- THE STRATEGIC VALUE OF PRODUCTIVITY-RELATED OUTCOMES IN CLINICAL TRIALS, BURDEN OF ILLNESS STUDIES, AND POST-MARKETING RESEARCH

    Sep 1, 2001, 00:00

  • DS1- PATIENT-REPORTED OUTCOMES- A COMPARISON OF TWO DATA-CAPTURE METHODS

    Sep 1, 2001, 00:00

  • PRP9- COST-OF-ILLNESS STUDY OF PATIENTS WITH ALLERGIC ASTHMA AND SEASONAL ALLERGIC RHINITIS IN GERMANY

    Sep 1, 2001, 00:00

  • PCN15- DIFFERENCES BETWEEN PREFERENCES FOR HEALTH STATES- THE CHEMOTHERAPY ADVERSE EVENT SELF-ASSESSED RESPONSE (CAESAR) QUESTIONNAIRE

    Sep 1, 2001, 00:00

  • PIN15- ECONOMIC COMPARISON OF SEQUENTIAL (IV TO PO) CIPROFLOXACIN/METRONIDAZOLE VS PIPERACILLIN/TAZOBACTAM FOR THE TREATMENT OF PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS

    Sep 1, 2001, 00:00

  • PIN22- PROPHYLAXIS AGAINST RSV, VARICELLA AND PNEUMOCOCCAL INFECTIONS- ECONOMIC-BASED DECISION-MAKING

    Sep 1, 2001, 00:00

  • PPN4- UTILITY ASSESSMENTS OF OPIOID TREATMENT IN THE US, CANADA AND AUSTRALIA FOR PATIENTS WITH CHRONIC NON-MALIGNANT PAIN

    Sep 1, 2001, 00:00

  • PMA12- RELATIONSHIP BETWEEN NONPARAMETRIC RECEIVER OPERATING CHARACTERISTIC ANALYSIS AND A LIKELIHOOD-RATIO TEST FOR MODEL SELECTION- I. A MONTE CARLO SIMULATION USING CONTINUOUS DATA

    Sep 1, 2001, 00:00

  • PAM7- THE CORRELATION BETWEEN ARTHRITIS SPECIFIC MEASURES AND SF-36 SCALES IN RHEUMATOID ARTHRITIS PATIENTS

    Sep 1, 2001, 00:00

  • PMH18- DEPRESSION AND QUALITY OF LIFE AND THEIR EFFECT ON HEALTH-CARE UTILIZATION

    Sep 1, 2001, 00:00

  • PAR8- A COST-EFFECTIVENESS ANALYSIS COMPARING LEVALBUTEROL AND ALBUTEROL IN THE TREATMENT OF MODERATE TO SEVERE ASTHMA

    Sep 1, 2001, 00:00

  • PCV10- INCIDENCE OF RHABDOMYOLYSIS IN PATIENTS INITIATED ON HMG CO-A REDUCTASE INHIBITOR THERAPY IN A MANAGED CARE ORGANIZATION

    Sep 1, 2001, 00:00

  • Retrospective Analysis of the Health-Care Costs of Bupropion Sustained Release in Comparison with Other Antidepressants

    Sep 1, 2001, 00:00

  • PCN6- MODELLING THE COST-EFFECTIVENESS OF DOCETAXEL IN THE SECOND LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC)

    Sep 1, 2001, 00:00

  • PQP2- ROLE OF HEALTH RELATED QUALITY OF LIFE OUTCOMES IN THE EUROPEAN DRUG REGULATORY PROCESS- A REVIEW OF THE EMEA DOCUMENTS

    Sep 1, 2001, 00:00

  • ID2- HEALTH VALUES FOR THE LIPODYSTROPHY SYNDROME

    Sep 1, 2001, 00:00

  • CN3- AN ECONOMIC MODEL FOR THE PHARMACOLOGICAL MANAGEMENT OF ADVANCED NON-SMALL CELL LUNG CANCER IN THE US

    Sep 1, 2001, 00:00

  • PHP24- CRITERIA FOR ASSESSING INTENSIVE CARE UNIT ADMISSIONS FROM THE EMERGENCY ROOM

    Sep 1, 2001, 00:00

  • PCV2- VENOUS THROMBOEMBOLIC (VTE) COMPLICATIONS FOLLOWING MAJOR ORTHOPEDIC SURGERY- FREQUENCY AND ECONOMIC CONSEQUENCES IN HOSPITAL

    Sep 1, 2001, 00:00

  • PMH12- PREVALENCE OF COMORBID ANXIETY AND DEPRESSION AMONG PATIENTS PRESCRIBED SSRI MONOTHERAPY

    Sep 1, 2001, 00:00

  • PMH15- THE IMPACT OF ALCOHOL ABUSE ON EMPLOYMENT IN SWITZERLAND

    Sep 1, 2001, 00:00

  • PCN3- USING LEVEL OF EVIDENCE CRITERIA IN THE EVALUATION OF PHARMACOECONOMIC RESULTS

    Sep 1, 2001, 00:00

  • PDG18- TREATMENT CHANGE FOLLOWING HEMOGLOBIN A1c TEST RESULTS AMONG DIABETIC PATIENTS

    Sep 1, 2001, 00:00

  • PMI3- INCORPORATING CLINICAL LEVEL-OF-EVIDENCE CRITERIA INTO A BREAST CANCER TREATMENT MODEL FOR JAPAN

    Sep 1, 2001, 00:00

  • ND1- INDIRECT COSTS DUE TO BACK PAIN IN THE UNITED STATES

    Sep 1, 2001, 00:00

  • PMA2- DEVELOPMENT OF COST-EFFECTIVE WEB-BASED OUTCOMES RESEARCH STUDIES AND DISEASE MANAGEMENT PROGRAMS

    Sep 1, 2001, 00:00

  • PDB7- COSTS AND EFFECTIVENESS OF INTENSIVE INSULIN THERAPY FOR TYPE 2 DIABETES

    Sep 1, 2001, 00:00

  • PAO5- COST ANALYSIS OF CELECOXIB AND CONVENTIONAL NSAIDS WITH OR WITHOUT GASTROPROTECTIVE AGENTS FOR TREATMENT OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS

    Sep 1, 2001, 00:00

  • PDG21- HUMANISTIC IMPACT OF HYPERGLYCEMIA IN TYPE 1 DIABETES MELLITUS

    Sep 1, 2001, 00:00

  • PDB6- AN EARLY LOOK AT TZD USE AMONG TYPE 2 DIABETES PATIENTS

    Sep 1, 2001, 00:00

  • POD3- THE PSYCHOMETRIC TESTING OF THE HUNGARIAN VERSION OF THE SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE

    Sep 1, 2001, 00:00

  • CE1- IMPACT OF CENSORED COST DATA ON THE OUTCOMES OF ECONOMIC EVALUATIONS

    Sep 1, 2001, 00:00

  • PAM22- STUDYING PREDICTORS OF FRACTURES AMONG OMNICARE NURSING HOME RESIDENTS

    Sep 1, 2001, 00:00

  • PDB9- COST-EFFECTIVENESS ANALYSIS OF A MULTIDISCIPLINARY DIABETES CARE CLINIC

    Sep 1, 2001, 00:00

  • PCV9- AN ECONOMIC ANALYSIS OF CONGESTIVE HEART FAILURE (CHF) IN THE LOUISIANA MEDICAID PROGRAM

    Sep 1, 2001, 00:00

  • PHP19- COST OF BLOOD PRODUCTS IN GERMAN HOSPITALS

    Sep 1, 2001, 00:00

  • POD8- VALIDATION OF VAGINAL CONTRACEPTION ACCEPTABILITY QUESTIONNAIRE

    Sep 1, 2001, 00:00

  • PID18- METHICILLIN-RESISTANT STAPHYLOCOCCUS SPECIES TREATMENT PATTERNS IN CANADA

    Sep 1, 2001, 00:00

  • HP5- USE OF THE SOJA METHOD FOR CHOOSING A HMG CO-A REDUCTASE INHIBITOR (STATIN) IN IRELAND

    Sep 1, 2001, 00:00

  • PMI25- THE RELATION OF DISTRIBUTION-AND ANCHOR-BASED APPROACHES ON INTERPRETATION OF CHANGES IN HEALTH-RELATED QUALITY OF LIFE

    Sep 1, 2001, 00:00

  • POD4- COST-CONSEQUENCES OF ORTHOPAEDIC SURGERY IN HAEMOPHILIA PATIENTS WITH INHIBITORS

    Sep 1, 2001, 00:00

  • POD2- USING CONTINGENT VALUATION IN A RCT FOR INDUCTION AND MAINTENANCE OF ANAESTHETIC AGENTS FOR DAY-CASE SURGERY

    Sep 1, 2001, 00:00

  • HP4- ASSESSING LIFESTYLE DRUGS FOR DRUG BENEFIT FORMULARIES- A COST-UTILITY ANALYSIS OF ORLISTAT AND SIBUTRAMINE FOR THE TREATMENT OF OBESITY IN ADULTS

    Sep 1, 2001, 00:00

  • PIN3- THE IMPACT OF DRUG COMPLIANCE ON THE COST OF TREATING HIV/AIDS IN AFRICA

    Sep 1, 2001, 00:00

  • PKU4- COST-MINIMISATION STUDY COMPARING SIMULECT VERSUS THYMOGLOBULINE IN RENAL TRANSPLANT INDUCTION

    Sep 1, 2001, 00:00

  • PMH12- THE COST OF TREATING SCHIZOPHRENIA IN ROUTINE CLINICAL PRACTICE- RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA (CNOMSS)

    Sep 1, 2001, 00:00

  • PCV6- ESTIMATING INCREMENTAL COSTS FOR ADDITIONAL HOSPITAL DAYS

    Sep 1, 2001, 00:00

  • PCV23- MODELLING THE COSTS OF ILLNESS IN THE MANAGEMENT OF CEREBROVASCULAR ACCIDENTS IN FRANCE

    Sep 1, 2001, 00:00

  • PCN1- CATEGORIZATION OF RISK OF PROSTATE CANCER- PILOT TEST OF CLINICAL OUTCOMES AND RISK PERCEPTIONS

    Sep 1, 2001, 00:00

  • PHP21- COST-BENEFIT ANALYSIS OF PREVENTING PRESCRIBING ERRORS BY HOSPITAL PHARMACISTS

    Sep 1, 2001, 00:00

  • PMH33- OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA- A COMPARISON OF COSTS AMONG TEXAS MEDICAID PATIENTS

    Sep 1, 2001, 00:00

  • IN1- ESTIMATING THE POTENTIAL HEALTH GAIN AND COST CONSEQUENCES OF INTRODUCING A PRE-SCHOOL DTPA PERTUSSIS BOOSTER INTO THE UK CHILD VACCINATION SCHEDULE

    Sep 1, 2001, 00:00

  • PAM23- VERTEBRAL FRACTURES AMONG GLUCOCORTICOID PATIENTS SIGNIFICANTLY INCREASE MEDICAL CARE COSTS

    Sep 1, 2001, 00:00

  • WW5- CREATIVE APPROACHES TO MODELING LIFE EXPECTANCY GAINS FOR ECONOMIC EVALUATION USING PUBLISHED DATA

    Sep 1, 2001, 00:00

  • PHP11- USE OF THE ANDERSEN HEALTH CARE SERVICES UTILIZATION BEHAVIORAL MODEL TO UNDERSTAND THE RELATIONSHIP BETWEEN HEALTH INSURANCE COVERAGE AND HEALTH CARE SERVICES UTILIZATION AMONG THE ELDERLY

    Sep 1, 2001, 00:00

  • PMI19- COST-EFFECTIVENESS OF TUBERCULOSIS PREVENTIVE THERAPY IN HIV-INFECTED PATIENTS- STUDY OF MISSING VARIABLES

    Sep 1, 2001, 00:00

  • PCV13- IMPACT ON QUALITY ADJUSTED LIFE YEARS OF ENOXAPARIN FOR PREVENTING THROMBOSIS AMONG HOSPITALIZED MEDICAL PATIENTS

    Sep 1, 2001, 00:00

  • HP6- THE IMPACT OF PIPELINE DRUGS ON UNITED STATES DRUG EXPENDITURE GROWTH TRENDS

    Sep 1, 2001, 00:00

  • CV1- ESTIMATING THE IMPACT OF ANTICOAGULATION QUALITY ON EVENT RATES

    Sep 1, 2001, 00:00

  • PAR23- DETERMINANTS OF INAPPROPRIATE ANTIBIOTIC PRESCRIBING

    Sep 1, 2001, 00:00

  • PHP23- DRUG REIMBURSEMENT PROGRAM FOR INDIGENT PATIENTS- AN ECONOMIC IMPACT ON THE HOSPTAL ADMINISTRATION BUDGET

    Sep 1, 2001, 00:00

  • PHP10- THE ROAD TO JAPAN/KOREA 2002- PROSPECTS FOR JAPANESE PHARMACOECONOMICS

    Sep 1, 2001, 00:00

  • PCV25- A COST STUDY OF COMMON PRACTICE TREATMENT FOR CRITICAL LIMB ISCHEMIA IN MOSCOW, RUSSIA

    Sep 1, 2001, 00:00

  • DG2- THE INCREMENTAL COST OF DIABETES IN CHRONIC ILLNESS CO-OCCURRENCES

    Sep 1, 2001, 00:00

  • PUR3- PERSISTENCE OF THERAPY WITH DRUGS FOR OVERACTIVE BLADDER

    Sep 1, 2001, 00:00

  • PCV21- COST-EFFECTIVENESS ANALYSIS OF ABCIXIMAB, EPTIFIBATIDE, AND TIROFIBAN IN PATIENTS WITH CORONARY SYNDROMES

    Sep 1, 2001, 00:00

  • PMH22- PATTERNS OF ANTIDEPRESSANT USE AND HEALTH CARE COSTS IN DEPRESSED PATIENTS WHO RECEIVED SSRI THERAPY

    Sep 1, 2001, 00:00

  • PCV36- EVALUATION OF COMPLIANCE AND PERSISTENCE WITH HMG-COA REDUCTASE INHIBITORS AFTER A MYOCARDIAL INFARCTION USING PHARMACY CLAIMS DATA

    Sep 1, 2001, 00:00

  • PHP11- REVIEW AND ANALYSIS OF DIFFERENT METHODOLOGIES FOR THE CALCULATION AND DISTRIBUTION OF PRIMARY HEALTH CARE PHARMACEUTICAL BUDGETS IN EUROPE

    Sep 1, 2001, 00:00

  • PIN9- COST-BENEFIT ANALYSIS OF VACCINATING HEALTHY WORKING ADULTS AGAINST INFLUENZA IN THE NETHERLANDS

    Sep 1, 2001, 00:00

  • PCN12- COST-UTILITY ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER

    Sep 1, 2001, 00:00

  • PRP5- ESTIMATES OF LOST PRODUCTIVE WORK TIME ASSOCIATED WITH ALLERGIC RHINITIS (AR)

    Sep 1, 2001, 00:00

  • CV2- A SIX YEAR FOLLOW-UP STUDY OF THE RELATIONSHIP BETWEEN MORTALITY, HOSPITALISATION AND ADHERENCE TO STATIN TREATMENT AFTER FIRST MYOCARDIAL INFARCTION

    Sep 1, 2001, 00:00

  • PCN5- DOCETAXEL/DOXORRUBICIN (DD) AS FIRST LINE CHEMOTHERAPY- QUALITY OF LIFE (QOL) IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC)

    Sep 1, 2001, 00:00

  • WW4- A NEW APPROACH TO DISEASE MODELING WITH NUMEROUS COMPARATORS AND MULTIPLE DECISION TREES

    Sep 1, 2001, 00:00

  • PKU6- INTERNATIONAL PSYCHOMETRIC VALIDATION AND CROSS-CULTURAL EQUIVALENCE OF A URINARY INCONTINENCE SPECIFIC QOL SCALE (CONTILIFE) IN SIX EUROPEAN COUNTRIES

    Sep 1, 2001, 00:00

  • EM2- THE IMPACT OF HOSPITAL COSTING METHODS ON STATISTICAL POWER IN MULTINATIONAL CLINICAL TRIALS

    Sep 1, 2001, 00:00

  • PPN21- MIGRAINE IN FRANCE IN 2000-THERAPEUTICAL DATA

    Sep 1, 2001, 00:00

  • PAR19- IMPACT OF THE ADDITION OF SALMETEROL TO THE TREATMENT OF ASTHMA PATIENTS IN A MEDICAID FEE-FOR-SERVICE POPULATION

    Sep 1, 2001, 00:00

  • PAR7- VALIDATION OF A MODEL OF SEVERITY OF ILLNESS IN CHRONIC RESPIRATORY DISEASE

    Sep 1, 2001, 00:00

  • PIN4- A RETROSPECTIVE ANALYSIS OF TREATMENT PATTERNS AND COSTS IN EXTERNAL GENITAL WARTS FOR THE NETHERLANDS

    Sep 1, 2001, 00:00

  • PHP19- USING FINANCIAL RATIOS TO COMPARE PHARMACY SPENDING IN THE DEPARTMENT OF VETERANS AFFAIRS

    Sep 1, 2001, 00:00

  • PAO6- COST-EFFECTIVENESS ANALYSIS OF USING CELECOXIB IN THE TREATMENT OF OSTEOARTHRITIS

    Sep 1, 2001, 00:00

  • POD1- ESTIMATING THE SEMI-FIXED COSTS OF A DAY-CASE EPISODE

    Sep 1, 2001, 00:00

  • PDB13- OPTIMIZATION OF DIABETES MANAGEMENT IN GERMANY USING A COMPUTER BASED OUTCOME PROGNOSES MODEL

    Sep 1, 2001, 00:00

  • MH4- APPLICATION OF THE RASCH MODEL TO THE SF36 MENTAL HEALTH 5 ITEM SCALE (MH5)

    Sep 1, 2001, 00:00

  • PCV18- COST EFFECTIVENESS OF ENOXAPARIN VS. UNFRACTIONATED HEPARIN FOR THE PROPHYLAXIS OF DVT AND SUBSEQUENT LONG-TERM COMPLICATIONS IN TOTAL HIP REPLACEMENT SURGERY IN THE UNITED KINGDOM

    Sep 1, 2001, 00:00

  • PDG16- BUDGETARY IMPACT OF TREATMENT GUIDELINES-THE EXAMPLE OF TYPE 2 DIABETES

    Sep 1, 2001, 00:00

  • PPN9- HOW IS PAIN FELT ACROSS COUNTRIES? THE SHORT-FORM MCGILL PAIN QUESTIONNAIRE (SF-MPQ) IN 10 LANGUAGES

    Sep 1, 2001, 00:00

  • PHP17- PATIENT OUTCOMES IN THE SEDATED ICU PATIENT

    Sep 1, 2001, 00:00

  • PAO1- THERAPEUTIC COMPARABILITY OF COX-2 INHIBITORS

    Sep 1, 2001, 00:00

  • PAR22- IMPACT OF LEVALBUTEROL VERSUS RACEMIC ALBUTEROL ON OUTPATIENT ASTHMA CARE CHARGES

    Sep 1, 2001, 00:00

  • PMH21- CLINICAL AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH OLANZAPINE IN PATIENTS WITH BIPOLAR DISORDER AS COMPARED WITH HALOPERIDOL

    Sep 1, 2001, 00:00

  • PMI18- MODELING ANTIBIOTIC EFFICACY BY INFECTIOUS AGENT AND PROBABILITY OF RESISTANCE

    Sep 1, 2001, 00:00

  • PHP27- THE RELATIONSHIP BETWEEN NATIONAL HEALTH INSURANCE EXPENDITURE AND THE BURDEN OF DISEASE- AN EVIDENCE-BASED STUDY IN TAIWAN

    Sep 1, 2001, 00:00

  • PHP9- COMPARISON OF TECHNOLOGY ASSESSMENT IN LARGE MEDICAL GROUPS AND HEALTH MAINTENANCE ORGANIZATIONS (HMOS)

    Sep 1, 2001, 00:00

  • PQP7- IS COMPLIANCE WITH DRUG TREATMENT CORRELATED WITH HEALTH RELATED QUALITY OF LIFE?

    Sep 1, 2001, 00:00

  • ID4- THE CONFUSION BETWEEN SEPTICEMIA AND SEVERE SEPSIS

    Sep 1, 2001, 00:00

  • PAR12- PROSPECTIVE USE OF WEB BASED TECHNOLOGY TO EVALUATE HEALTH OUTCOMES IN A LARGE COHORT OF SEVERE OR DIFFICULT TO TREAT ASTHMATICS

    Sep 1, 2001, 00:00

  • PIN16- COST-EFFECTIVENESS OF TERBINAFINE AND ITRACONAZOLE IN TOENAIL ONYCHOMYCOSIS IN POLAND- MODELLING STUDY WITH THREE-YEAR TIME HORIZON

    Sep 1, 2001, 00:00

  • PMH36- DOSING OF BENZODIAZEPINE HYPNOTICS IN ELDERLY PATIENTS

    Sep 1, 2001, 00:00

  • PEE12- THE WILLINGNESS TO PAY FOR PHARMACOTHERAPY OF ATOPIC DERMATITIS

    Sep 1, 2001, 00:00

  • PDB3- THE BURDEN OF ILLNESS OF DIABETES MELLITUS TYPE 2 IN GERMANY- A PILOT STUDY

    Sep 1, 2001, 00:00

  • CV7- COST-EFFECTIVENESS OF CARDIOVASCULAR DISEASE (CVD) PREVENTION BY REDUCING POSTPRANDIAL HYPERGLYCEMIA

    Sep 1, 2001, 00:00

  • PMH28- DEPRESSION AND HOMELESSNESS, A FRENCH INITIATIVE

    Sep 1, 2001, 00:00

  • PAO7- AN ECONOMIC EVALUATION OF THE COST OF EDEMA AND SYSTOLIC BLOOD PRESSURE DESTABILIZATION IN COX-2-TREATED PATIENTS WITH OSTEOARTHRITIS AND HYPERTENSION

    Sep 1, 2001, 00:00

  • PID11 PEGYLATED (40KDA) INTERFERON ALFA-2A (PEGASYS) SIGNIFICANTLY IMPROVES TOLERABILITY, QUALITY OF LIFE, AND WORK PRODUCTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C

    Sep 1, 2001, 00:00

  • PIN18- DIRECT AND INDIRECT COSTS OF RESPIRATORY INFECTIONS

    Sep 1, 2001, 00:00

  • PDG27- HEALTH STATE UTILITIES IN GERD PATIENTS WITH HEARTBURN A STUDY IN GERMANY AND SWEDEN

    Sep 1, 2001, 00:00

  • PQP11- THE HEALTH AND WORK QUESTIONNAIRE (HWQ)- AN INSTRUMENT FOR ASSESSING WORKPLACE PRODUCTIVITY IN RELATION TO WORKER HEALTH

    Sep 1, 2001, 00:00

  • PAM3- THE COST OF OSTEOPOROTIC FRACTURES IN THE UNITED KINGDOM

    Sep 1, 2001, 00:00

  • PEE8- QUALITY OF LIFE OF FRENCH PATIENTS TREATED FOR PRIMARY OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION

    Sep 1, 2001, 00:00

  • PMH9- ECONOMIC ANALYSIS OF PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER

    Sep 1, 2001, 00:00

  • RS2- USING SELF-ADMINISTERED DIRECT TTO QUESTIONS TO ELICIT UTILITY VALUES FOR ASTHMATIC PATIENTS WITH DIFFERENT SEVERITY OF DISEASE

    Sep 1, 2001, 00:00

  • PEE5- INAPPROPRIATE ANTIBIOTIC PRESCRIBING AND ECONOMIC OUTCOMES FOR PEDIATRIC OTITIS MEDIA

    Sep 1, 2001, 00:00

  • PAO13- UNITED STATES COMMUNITY PHARMACISTS INTERVENTIONS WITH FEMALE PATIENTS REGARDING OSTEOPOROSIS

    Sep 1, 2001, 00:00

  • PDG7- THE LIFETIME DIRECT MEDICAL COSTS OF MANAGING DIABETES AND ITS COMPLICATIONS IN FRANCE

    Sep 1, 2001, 00:00

  • PMA3- DOES WHERE YOU LIVE AFFECT IF AND HOW YOU DISCOUNT FUTURE COSTS AND BENEFITS IN ECONOMIC EVALUATION? SHOULD IT?

    Sep 1, 2001, 00:00

  • PMH25- A MODEL COMPARING OLANZAPINE AND ZIPRASIDONE IN PATIENTS WITH SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • MS2- RESPONSIVENESS TO CHANGE OF THE SF-36 IN RAPOLO, A LONGITUDINAL STUDY OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ETANERCEPT

    Sep 1, 2001, 00:00

  • CN2- EFFECT OF INCLUDING (VERSUS EXCLUDING) FATES WORSE THAN DEATH ON UTILITY MEASUREMENT

    Sep 1, 2001, 00:00

  • MH3- CLINICAL ASSESSMENT OF QUALITY OF LIFE AMONG SCHIZOPHRENIA PATIENTS WITH DEFICIT SYNDROME

    Sep 1, 2001, 00:00

  • PMH29- COST ANALYSIS OF OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF UNCONTROLLED SCHIZOPHRENIA

    Sep 1, 2001, 00:00

  • PID5- MOXIFLOXACIN VS AMOXICILLIN/CLAVULANATE IN THE TREATMENT OF ACUTE MAXILLARY SINUSITIS (AMS)- EFFICACY, SAFETY AND PATIENT-REPORTED OUTCOMES IN PRIMARY CARE

    Sep 1, 2001, 00:00

  • PMH16- ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA- ADVERSE EVENTS, NON-COMPLIANCE AND COST

    Sep 1, 2001, 00:00

  • PMI23- CHANGING STRATEGIES IN THE PROMOTION OF HEALTH CARE RESEARCH IN GERMANY

    Sep 1, 2001, 00:00

  • PCN3- PREDICTORS OF CHEMOTHERAPY-RELATED NEUTROPENIA- A REVIEW OF THE CLINICAL LITERATURE

    Sep 1, 2001, 00:00

  • HP3- INCORPORATING CLINICAL OUTCOMES AND ECONOMIC CONSEQUENCES INTO DRUG FORMULARY DECISIONS- EVALUATION OF 30 MONTHS OF EXPERIENCE

    Sep 1, 2001, 00:00

  • POD12- BENIGN PROSTATIC HYPERPLASIA- RECOGNITION OF THE CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE

    Sep 1, 2001, 00:00

  • PAM10- THE IMPACT OF EARLY RHEUMATOID ARTHRITIS ON PRODUCTIVITY

    Sep 1, 2001, 00:00

  • CV1- THE VALUE OF COMPLIANCE- EVIDENCE FROM TWO PATIENT COHORTS

    Sep 1, 2001, 00:00

  • POD13- A RISK-ASSESSMENT MODEL FOR ERECTILE DYSFUNCTION- THE SEXUAL-HEALTH INVENTORY FOR MEN AND RELATED MEDICAL CONDITIONS

    Sep 1, 2001, 00:00

  • CE2- HANDLING MISSING DATA IN STOCHASTIC COST-EFFECTIVENESS ANALYSIS- THE IMPACT OF IMPUTATION METHODS ON ESTIMATES OF THE PHYSICAL QUANTITIES OF MEDICAL CARE RESOURCE USE

    Sep 1, 2001, 00:00

  • PID8- COSTS OF HEALTH CARE FOR HEPATITIS C-INFECTED MEMBERS IN A MANAGED CARE ORGANIZATION (MCO)

    Sep 1, 2001, 00:00

  • PPN8- PSYCHOMETRIC EVALUATION OF WIDELY USED PAIN MEASURES FOR PURPOSE OF COMPUTERIZED DYNAMIC PAIN ASSESSMENT

    Sep 1, 2001, 00:00

  • PCN4- COMPARING MEAN VERSUS MEDIAN SURVIVAL AS A PRELUDE TO COST-EFFECTIVENESS (C/E) ANALYSES

    Sep 1, 2001, 00:00

  • PAR3- THE STANDARDIZED ASTHMA-RELATED QUALITY OF LIFE QUESTIONNAIRE (AQLQ-S)- DOES SOCIOECONOMIC STATUS EFFECT MEASUREMENTS?

    Sep 1, 2001, 00:00

  • RS3- PSYCHOMETRIC EVALUATION OF THE CAP-SYM QUESTIONNAIRE- A NEW, PATIENT-BASED MEASURE OF SYMPTOMS IN COMMUNITY ACQUIRED PNEUMONIA

    Sep 1, 2001, 00:00

  • PCN19- CHOICE OF OPTIMAL ANTI-EMETIC STRATEGIES IN CANCER THERAPY

    Sep 1, 2001, 00:00

  • PCN2- COST OF TREATMENT AND FOLLOW UP OF BREAST CANCER. A RETROSPECTIVE EVALUATION IN A COMPREHENSIVE CANCER CENTRE

    Sep 1, 2001, 00:00

  • PGI4- HEALTH-RELATED QUALITY OF LIFE (HRQOL) DATA REVEAL DIFFERENCES AMONG CLINICAL 'RESPONDERS'

    Sep 1, 2001, 00:00

  • Modeling for Health Care and Other Policy Decisions- Uses, Roles, and Validity

    Sep 1, 2001, 00:00

  • PCV34- DECISION ANALYSIS MODEL OF ABCIXIMAB, EPTIFIBATIDE OR STANDARD THERAPY IN ELECTIVE STENT PLACEMENT- A CANADIAN PERSPECTIVE

    Sep 1, 2001, 00:00

  • PCV24- BEYOND THE FIRST YEAR- PATTERNS AND PREDICTORS OF LONG-TERM STATIN UTILIZATION

    Sep 1, 2001, 00:00

  • PMA17- THE EUROPEAN SERVICE MAPPING SCHEDULE (ESMS)- A NEW INSTRUMENT FOR MENTAL HEALTH SERVICES RESEARCH, RESULTS OF A FRENCH STUDY

    Sep 1, 2001, 00:00

  • EM1- RISK ATTITUDE- ASSOCIATION WITH MAGNITUDE OF RISK AND PATIENT CHARACTERISTICS

    Sep 1, 2001, 00:00

  • PMH8- SCHIZOPHRENIA OUTCOMES RESEARCH STUDY IN SPAIN- TOLERABILITY AND ECONOMIC RESULTS WITH ATYPICAL ANTIPSYCHOTICS

    Sep 1, 2001, 00:00

  • PMH11- RETROSPECTIVE ECONOMIC EVALUATION OF MIRTAZAPINE, VENLAFAXINE XR AND SERTRALINE IN A MANAGED CARE POPULATION

    Sep 1, 2001, 00:00

  • PMA7- CONTROLLING FOR BIASES FROM MEASUREMENT ERRORS IN HEALTH OUTCOMES RESEARCH USING STRUCTURAL EQUATION MODELING

    Sep 1, 2001, 00:00

  • PHP3- PHARMACOECONOMIC FELLOWSHIPS- STRUCTURE, PROCESS, AND OUTCOMES

    Sep 1, 2001, 00:00

  • PMH5- THE COST-EFFECTIVENESS OF QUETIAPINE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS PARTIALLY RESPONSIVE TO PREVIOUS ANTIPSYCHOTICS-AN ECONOMIC ANALYSIS OF THE PRIZE STUDY

    Sep 1, 2001, 00:00

  • PPN3- THE IMPACT OF DEMENTIA ON CAREGIVER QUALITY OF LIFE

    Sep 1, 2001, 00:00

  • PDG24- PHARMACOECONOMIC ASSESSMENT OF RABEPRAZOLE IN PEPTIC ULCER IN RUSSIA

    Sep 1, 2001, 00:00

  • WW2- USING LINKABLE CLINICAL AND ADMINISTRATIVE CLAIMS DATA TO IMPROVE OUTCOMES RESEARCH- SELECTED CASE STUDIES FROM ONCOLOGY AND DIABETES MELLITUS

    Sep 1, 2001, 00:00

  • HP3- REGIONAL VARIATION IN PRESCRIPTION USE IN THE UNITED STATES

    Sep 1, 2001, 00:00

  • PGI15- COMPUTERIZED ASSESSMENT OF COMPLICATIONS FOLLOWING COLORECTAL SURGERY

    Sep 1, 2001, 00:00

  • PDB11- ECONOMIC OUTCOMES OF DIABETES AMONG AN EMPLOYED POPULATION

    Sep 1, 2001, 00:00

  • PID3- TRENDS IN INPATIENT COSTS FOR ACUTE PANCREATITIS IN THE UNITED STATES

    Sep 1, 2001, 00:00

  • CH2- TRANSITION IN HEALTH-RELATED QUALITY OF LIFE IN U.S. ELDERLY

    Sep 1, 2001, 00:00

  • PEE10- IS NON-CONTACT NORMOTHERMIC WOUND THERAPY COST-EFFECTIVE FOR THE TREATMENT OF STAGE 3 AND 4 PRESSURE ULCERS?

    Sep 1, 2001, 00:00

  • PMH21- QUALITY OF LIFE OF NON-INSTITUTIONAL CAREGIVERS OF SCHIZOPHRENIC PATIENTS- CONTRIBUTION OF QUALITATIVE INTERVIEWS TO QUESTIONNAIRE GENERATION

    Sep 1, 2001, 00:00

  • CV3- VASOPEPTIDASE INHIBITOR REDUCES IN-HOSPITAL COSTS FOR CONGESTIVE HEART FAILURE PATIENTS- RESULTS FROM THE IMPRESS TRIAL

    Sep 1, 2001, 00:00

  • MH2- FUTURE EMPLOYABILITY- A NEW APPROACH TO COST-EFFECTIVENESS ANALYSIS OF ANTIPSYCHOTIC THERAPY

    Sep 1, 2001, 00:00

  • PIN14- A STUDY ON THE HEALTH EFFECTS OF FLU AND FLU-LIKE ILLNESSES IN THE WORKING POPULATION AND THEIR COST IMPACT ON A BIG CORPORATION IN HONG KONG

    Sep 1, 2001, 00:00

  • PCN14- CHOICE OF LOCALIZED BREAST CANCER TREATMENTS IN A MEDICARE POPULATION- A COMPARISON OF OUTCOMES AND COSTS

    Sep 1, 2001, 00:00

  • PAM5- INVESTIGATING THE CONSTRUCT VALIDITY OF A DISEASE SPECIFIC AND A GENERAL QUALITY OF LIFE INSTRUMENTS OF PATIENTS WITH RHEUMATOID ARTHRITIS

    Sep 1, 2001, 00:00

  • MD2- ANALYSIS OF THE IMPACT OF ASSISTIVE LIVING DEVICES ON SELF-ASSESSED HEALTH STATUS RATING

    Sep 1, 2001, 00:00

  • WW12- USE OF MEDICATION COMPLIANCE DATA IN OUTCOME ANALYSES

    Sep 1, 2001, 00:00

  • PDB14- IMPACT OF A DIABETES DISEASE MANAGEMENT PROGRAM- A RETROSPECTIVE CLAIMS-BASED EVALUATION

    Sep 1, 2001, 00:00

  • PCV34- STOP SMOKING CESSATION TARGET- OBSERVATION PROGRAM, THE FRENCH PHARMACISTS PROGRESS

    Sep 1, 2001, 00:00

  • PPN19- COMPARISON OF HUI2 AND HUI3 SCORES FOR PATIENTS WITH ALZHEIMERS DISEASE

    Sep 1, 2001, 00:00

  • RS1- OUTCOME ASSESSMENT IN PEDIATRIC ASTHMA- A COMPARISON OF SYMPTOM-FREE TIME AND MULTI-ATTRIBUTE SCALE

    Sep 1, 2001, 00:00

  • PCV35- COMPARABILITY OF PUBLISHED STUDIES ON COST-EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY- DO THE RESULTS HELP THE DECISION-MAKING PROCESS?

    Sep 1, 2001, 00:00

  • PID27- DOES A DAY STILL MAKE A DIFFERENCE? A DECISION ANALYSIS OF ADULT STREPTOCOCCAL PHARYNGITIS

    Sep 1, 2001, 00:00

  • PCV33- IMPACT OF INSURANCE TYPES ON PATTERNS OF ANTIHYPERTENSIVE DRUG UTILIZATION- DIURETICS OR BETA-BLOCKERS VS. ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR CALCIUM CHANNEL BLOCKERS

    Sep 1, 2001, 00:00

  • PMA14- BAYESIAN DECISION ANALYSIS IN OUTCOME STUDIES WITH SMALL NUMBERS OF EVENTS- A SIMULATION BASED PREDICTION APPROACH

    Sep 1, 2001, 00:00

  • PMI14- TO TRANSLATE OR TO ADAPT-WHAT DO THE QUESTIONS MEAN?

    Sep 1, 2001, 00:00

  • PAM4- USE OF COX 2 NSAIDS IN SUBJECTS WITHOUT RISK OF GASTROINTESTINAL SIDE EFFECTS

    Sep 1, 2001, 00:00

  • PHP23- HOSPITAL READMISSIONS OF OLDER PEOPLE

    Sep 1, 2001, 00:00

  • PPN20- ESTIMATED RESOURCE USE AND COST OF MITOXANTRONE VS PLACEBO IN PATIENTS WITH PROGRESSIVE-RELAPSING AND SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS- RESULTS FROM THE MIMS TRIAL

    Sep 1, 2001, 00:00

  • PCV16- COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN VERSUS UNFRACTIONATED HEPARIN IN ACUTE CORONARY SYNDROME PATIENTS IN POLAND

    Sep 1, 2001, 00:00

  • PCV30- A POPULATION-BASED EUROPEAN STUDY OF PERSISTENCE IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS

    Sep 1, 2001, 00:00

  • PCV29- ECONOMIC OUTCOMES OF PATIENTS RECEIVING CARVEDILOL COMPARED TO THOSE RECEIVING NO BETA-BLOCKER THERAPY FOR THE TREATMENT OF CONGESTIVE HEART FAILURE IN A MANAGED CARE ORGANIZATION

    Sep 1, 2001, 00:00

  • PMH17- LONG-TERM ECONOMIC BENEFITS OF ANTIPSYCHOTIC USE

    Sep 1, 2001, 00:00

  • PGI2- ALTERNATIVE MANAGEMENT STRATEGIES FOR DYSPEPSIA

    Sep 1, 2001, 00:00

  • DB1- ESTIMATING HEALTH-CARE COSTS ASSOCIATED WITH DIABETES-RELATED COMPLICATIONS USING DATA FROM THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY (UKPDS)

    Sep 1, 2001, 00:00

  • PGI16- ANALYSIS OF THE LONG-TERM COSTS, SAVINGS AND EFFECTS GENERATED BY INFLIXIMAB TO NORMALIZE QUALITY OF LIFE IN PATIENTS WITH CROHNS DISEASE

    Sep 1, 2001, 00:00

  • PAO12- DIRECT MEDICAL COST OF OSTEOPOROSIS IN THE UNITED STATES- PROJECTIONS FOR 2000-2025

    Sep 1, 2001, 00:00

  • PHP16- HOW RESPONSIVE ARE OUR HEALTH CENTRES?

    Sep 1, 2001, 00:00

  • PAR15- COMPARISON OF HEALTH CARE RESOURCE UTILIZATION OF COPD PATIENTS ON CILOMILAST, 15 MG BID VERSUS PLACEBO

    Sep 1, 2001, 00:00

  • PCN8- COST OF MANAGING SEVERE HYPERURICEMIA AND TUMOUR LYSIS SYNDROME IN HAEMATOLOGIC MALIGNANCIES

    Sep 1, 2001, 00:00

  • PCV40- COST-EFFECTIVENESS OF LIPID LOWERING INTERVENTIONS IN A NATIVE AMERICAN CARDIOVASCULAR RISK REDUCTION PROGRAM

    Sep 1, 2001, 00:00

  • PAO9- DISABILITY, RESOURCE UTILISATION, AND WORK ABSENCES ASSOCIATED WITH OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA)- AN INTERNATIONAL DATABASE ANALYSIS

    Sep 1, 2001, 00:00

  • PCV9- COST-EFFECTIVENESS OF EPTIFIBATIDE IN THE UK BASED ON PURSUIT TRIAL

    Sep 1, 2001, 00:00

  • PCV1- A COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN AS PREVENTION OF ISCHEMIC EVENTS IN PATIENTS WITH ESTABLISHED PERIPHERAL ARTERY DISEASE

    Sep 1, 2001, 00:00

  • QL1- DOES SOCIOECONOMIC STATUS AFFECT THE VALUATION OF HEALTH?

    Sep 1, 2001, 00:00

  • PAO14- THE COST-EFFECTIVENESS OF CALCIUM AND VITAMIN D3 SUPPLEMENTATION FOR THE PREVENTION OF OSTEOPOROTIC HIP FRACTURES IN SWEDEN

    Sep 1, 2001, 00:00

  • RP1- DOES ILLNESS-RELATED LOST PRODUCTIVE WORK TIME VARY BY JOB DEMAND OR JOB CONTROL- A CASE STUDY OF ALLERGIC RHINITIS (AR)

    Sep 1, 2001, 00:00

  • PCV22- IN-PATIENT AND OUT-PATIENT RESOURCE UTILIZATION AMONG PATIENTS WITH ACUTE ISCHEMIC STROKE-THE VA EXPERIENCE

    Sep 1, 2001, 00:00

  • PND1- ASSOCIATION OF FAMILY HARDINESS WITH WORK PRODUCTIVITY AND ACTIVITY IN FAMILIES OF PEDIATRIC PATIENTS WITH EPILEPSY

    Sep 1, 2001, 00:00

  • PID16- COST BURDEN OF VARICELLA-ZOSTER VIRUS INFECTION IN A MANAGED CARE SETTING

    Sep 1, 2001, 00:00

  • PHP4- WHAT IS A VALID PRESCRIBING INDICATOR?

    Sep 1, 2001, 00:00

  • PDB12- A PHARMACOECONOMIC ANALYSIS OF WEIGHT-REDUCTION THERAPY IN A HYPOTHETICAL COHORT OF OBESE CHINESE PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE

    Sep 1, 2001, 00:00

  • PEE8- FOUR YEAR COST-EFFECTIVENESS OF INITIAL TRABECULECTOMY VERSUS CONVENTIONAL THERAPY IN PRIMARY OPEN-ANGLE GLAUCOMA (POAG)

    Sep 1, 2001, 00:00

  • PID12- AVERTING FUTURE AIDS CASES- MODELING COSTS OF INTERVENTIONS WITH OUT-OF-TREATMENT SUBSTANCE ABUSERS

    Sep 1, 2001, 00:00

  • PCN15- QOL CHANGE OVER TIME POST-REINFUSION OF PBPC IN HIGH DOSE TREATMENT OF NON-HODGKINS FOLLICULAR LYMPHOMA (N-HFL) WITH AND WITHOUT FILGRASTIM USE

    Sep 1, 2001, 00:00

  • PAM2- AN ECONOMIC EVALUATION OF OSTEOPOROSIS MEDICATION USE PATTERNS IN A MANAGED CARE ORGANIZATION- A TIME TO FRACTURE ANALYSIS

    Sep 1, 2001, 00:00

  • PPN16- ECONOMIC BURDEN AND LOSS IN QUALITY OF LIFE DUE TO LOW BACK PAIN

    Sep 1, 2001, 00:00

  • PID28- COMPARING DIFFERENCES IN CLINICAL EFFECTIVENESS, NEPHROTOXICITY, AND COST-EFFECTIVENESS OF AMINOGLYCOSIDE THERAPY BETWEEN ALTERNATIVE DOSING PROTOCOLS

    Sep 1, 2001, 00:00
  • «
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170 (current)
  • »